Parstatin, the cleaved peptide on proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 2, 2009, Pages 378-389

  Zania, Panagiota ^a   Gourni, Despina ^a   Aplin, Alfred C ^b   Nicosia, Roberto F ^b,c   Flordellis, Christodoulos S ^a   Maragoudakis, Michael E ^a   Tsopanoglou, Nikos E ^a,d  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CASPASE; CELL PENETRATING PEPTIDE; LIGAND; PARSTATIN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL GROWTH; CELL MIGRATION; CHICK EMBRYO; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; EMBRYO; FISCHER 344 RAT; HUMAN; HUMAN CELL; HYDROPHOBICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CAPILLARIES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHICK EMBRYO; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RECEPTOR, PAR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59649104461     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.145664     Document Type: Article

References (32)

1. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, and Kuliopulos A (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120:303-313.
2. Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S, and Karpatkin S (2006) Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res 66: 4125-4132.
3. Claytor RB, Michelson AD, Li JM, Frelinger AL 3rd, Rohrer MJ, Garnette CS, Barnard MR, Krueger LA, and Furman MI (2003) The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin. J Vasc Surg 37:440-445.
4. Darmoul D, Gratio V, Devaud H, Lehy T, and Laburthe M (2003) Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 162:1503-1513.
5. 1-linked Ras/mitogen-activated protein kinase pathway. J Biol Chem 274:13718-13727.
6. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, and Bar-Shavit R (1998) Thrombin receptor overexpression in malignant and physiological invasion process. Nat Med 4:909-914.
7. Furman MI, Liu L, Benoit SE, Becker RC, Barnard MR, and Michelson AD (1998) The cleaved peptide of the thrombin receptor is a strong platelet agonist. Proc Natl Acad Sci U S A 95:3082-3087.
8. Furman MI, Nurden P, Berndt MC, Nurden AT, Benoit SE, Barnard MR, Ofosu FA, and Michelson AD (2000) The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system. Thromb Haemost 84:897-903.
9. Hirano K (2007) The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 27:27-36.
10. Kaushal V, Kohli M, Dennis RA, Siegel ER, Chiles WW, and Mukunyadzi P (2006) Thrombin receptor expression is upregulated in prostate cancer. Prostate 66:273-282.
11. Köchl R, Alken M, Rutz C, Krause G, Oksche A, Rosenthal W, and Schülein R (2002) The signal peptide of the G protein-coupled human endothelin B receptor is necessary for translocation of the N-terminal tail across the endoplasmic reticulum membrane. J Biol Chem 277:16131-16138.
12. Leger AJ, Covic L, and Kuliopulos A (2006) Protease-activated receptors in cardiovascular diseases. Circulation 114:1070-1077.
13. Lin YZ, Yao SY, Veach RA, Torgerson TR, and Hawiger J (1995) Inhibition of nuclear translocation of transcriptional factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 270:14255-14258.
14. Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, and Wallace JL (2005) Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A 102:216-220.
15. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, and Coughlin SR (1992) Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 90:1614-1621.
16. Nyberg P, Xie L, and Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65:3967-3979.
17. Ossovskaya VS and Bunnett NW (2004) Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84:579-621.
18. Pyriochou A, Beis D, Koika V, Potytarchou C, Papadimitriou E, Zhou Z, and Papapetropoulos A (2006) Soluble guanylyl cyclase activation promotes angiogenesis. J Pharmacol Exp Ther 319:663-671.
19. Ramachandran R, Klufas AS, Molino M, Ahuja M, Hoxie JA, and Brass LF (1997) Release of the thrombin receptor (PAR-1) N-terminus from the surface of human platelets activated by thrombin. Thromb Haemost 78:1119-1124.
20. Rapraeger AC, Krufka A, and Olwin BB (1991) Requirement of heparin sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252:1705-1708.
21. Riewald M, Petrovan RJ, Donner A, Mueller BM, and Ruf W (2002) Activation of endothelial cell protease-activated receptor 1 by the protein C pathway. Science 296:1880-1882.
22. Roovers K and Assoian RK (2003) Effects of Rho kinase and actin stress fibers on sustained extracellular signal-regulated kinase activity and activation of G([1]) phase cyclin-dependent kinases. Mol Cell Biol 23:4283-4294.
23. Rutz C, Renner A, Alken M, Schulz K, Beyermann M, Wiesner B, Rosenthal W, and Schülein R (2006) The corticotrophin-releasing factor receptor type 2a contains an N-terminal pseudo signal peptide. J Biol Chem 281:24910-24921.
24. Tsopanoglou NE and Maragoudakis ME (1999) On the mechanism of thrombininduced angiogenesis: potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J Biol Chem 274:23969-23976.
25. Tsopanoglou NE and Maragoudakis ME (2004) Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost 30:63-69.
26. Tsopanoglou NE and Maragoudakis ME (2007) Inhibition of angiogenesis by small-molecule antagonists of protease-activated preceptor-1. Semin Thromb Hemost 33:680-687.
27. van Heerde WL, Robert-Offerman S, Dumont E, Hofstra L, Doevendans PA, Smits JF, Daemen MJ, and Reutelingsperger CP (2000) Markers of apoptosis in cardiovascular tissues: focus on annexin V. Cardiovasc Res 45:549-559.
28. Vivès E, Schmidt J, and Pèlegrin A (2008) Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 1786:126-138.
29. Vu TK, Hung DT, Wheaton VI, and Coughlin SR (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor action. Cell 64:1057-1068.
30. Yayon A, Klagsbrun M, Esko JD, Leder P, and Ornitz DM (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841-848.
31. Zania P, Kritikou S, Flordellis CS, Maragoudakis ME, and Tsopanoglou NE (2006) Blockage of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. J Pharmacol Exp Ther 318:246-254.
32. Zhu WH and Nicosia RF (2002) The thin prep rat aortic ring assay: a modified method for the characterization of angiogenesis in whole mounts. Angiogenesis 5:81-86.